Donanemab Chemische Eigenschaften,Einsatz,Produktion Methoden

History

Donanemab, developed by Eli Lilly and Company, is a monoclonal antibody used for the treatment of Alzheimer's disease. In July 2024, the U.S. Food and Drug Administration (FDA) has effectively approved the Kisunla (donanemab-azbt) injection for the treatment of AD in patients with mild cognitive impairment or mild dementia, in which the drugs were tested in clinical trials. Kisunla is given intravenously, and the recommended dose is given every 4 weeks.

Donanemab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Donanemab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Wuhan Maixi Biotechnology Co., Ltd	18007167883 18007167883	Service@mabnus.com	China	909	58
Shanghai YuanYe Biotechnology Co., Ltd.	13636370518	shyysw007@163.com	China	89686	60
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24957	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9865	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7101	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11972	58
Wuhan Acumen Bio-Technology Co.,ltd	027-027-16602739303 16602739303	673003916@qq.com	China	4590	58
Changsha Fuzhen Biotechnology Co.，LTD	15111215862 18229892877	3062105966@qq.com	China	5435	58

---

• Donanemab
• Research Grade Donanemab(DHC12502)
• Research Grade Donanemab
• Donaimab monoclonal antibody
• 1931944-80-7